MeSH term | MeSH ID | Detail |
---|---|---|
Tauopathies | D024801 | 6 associated lipids |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | D054218 | 5 associated lipids |
Epothilone d is a lipid of Polyketides (PK) class. Epothilone d is associated with abnormalities such as Tauopathies, Neutropenia, Neuropathy and Hematological Disease. The involved functions are known as Mutation, Apoptosis, Mitotic arrest, Cell Growth and Anabolism. Epothilone d often locates in Cytoskeleton, Axon, Cell Wall, Chromosomes and Spindle. The associated genes with epothilone D are SLC33A1 gene, Chromatin, GTF2I gene and HEXA gene.
To understand associated biological information of Epothilone D, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Epothilone D is suspected in Tauopathies, Neutropenia, Neuropathy, Hematological Disease and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Epothilone D
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Konner J et al. | Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. | 2012 | Invest New Drugs | pmid:22072399 |
Monk JP et al. | A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors. | 2012 | Invest New Drugs | pmid:21826439 |
Beer TM et al. | Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. | 2007 | Invest New Drugs | pmid:17618407 |
Bergstralh DT et al. | A comparison of signaling activities induced by Taxol and desoxyepothilone B. | 2004 | J Chemother | pmid:15700849 |
Burrell RC et al. | Synthesis of stable isotope-labeled epothilone D using a degradation-reconstruction approach. | 2015 | J Labelled Comp Radiopharm | pmid:26158758 |
Wang Z et al. | Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. | 2006 | J Pharm Biomed Anal | pmid:16616824 |
Jumaa M et al. | Kinetics and mechanism of degradation of epothilone-D: an experimental anticancer agent. | 2004 | J Pharm Sci | pmid:15459947 |
White JD et al. | Total synthesis of epothilone B, epothilone D, and cis- and trans-9,10-dehydroepothilone D. | 2001 | J. Am. Chem. Soc. | pmid:11389619 |
Tang L et al. | Generation of novel epothilone analogs with cytotoxic activity by biotransformation. | 2003 | J. Antibiot. | pmid:12670045 |
Nagano S et al. | Crystal structures of epothilone D-bound, epothilone B-bound, and substrate-free forms of cytochrome P450epoK. | 2003 | J. Biol. Chem. | pmid:12933799 |